Failed therapy and directions for the future in dyspepsia

Digestive Diseases

Volumn 26, Issue 3, 2008, Pages 218-224

  Holtmann, Gerald ^a   Gapasin, Judith ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Evidence based measures; Functional dyspepsia; Quality of life; Treatment

Indexed keywords

ARTICHOKE EXTRACT; BUSPIRONE; CARAWAY EXTRACT; CISAPRIDE; CLONIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; IBEROGAST; OCTREOTIDE; PANCREAS ENZYME; PEPPERMINT EXTRACT; PLACEBO; PLANT EXTRACT; PROKINETIC AGENT; PROTON PUMP INHIBITOR; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; SIMETHICONE; STOMACH SECRETION INHIBITOR; SUCRALFATE; SUMATRIPTAN; TRICYCLIC ANTIDEPRESSANT AGENT;

CLINICAL TRIAL; COGNITIVE THERAPY; CONSTIPATION; DIET; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DROWSINESS; DRUG EFFICACY; DYSPEPSIA; ECONOMIC ASPECT; ERADICATION THERAPY; HELICOBACTER PYLORI; HERBAL MEDICINE; HUMAN; HYPNOTHERAPY; INTERVENTION STUDY; LIFESTYLE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOLOGY; PSYCHOTHERAPY; QUALITY OF LIFE; REASSURANCE; REMISSION; REVIEW; RISK BENEFIT ANALYSIS; SOCIETY; THERAPY EFFECT; TREATMENT FAILURE; XEROSTOMIA;

CHRONIC DISEASE; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; DYSPEPSIA; EVIDENCE-BASED MEDICINE; FEMALE; FORECASTING; GASTROINTESTINAL AGENTS; HUMANS; MALE; PROGNOSIS; PSYCHOTHERAPY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 43449101198     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000121350     Document Type: Review

References (44)

1. Drossman DA: The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006;130:1377-1390.
2. Gschossmann JM, Haag S, Holtmann G: Epidemiological trends of functional gastrointestinal disorders. Dig Dis 2001;19:189-194.
3. Kindt S, Tack J: Impaired gastric accommodation and its role in dyspepsia. Gut 2006;55:1685-1691.
4. Lacy BE, Weiser K: Gastrointestinal motility disorders: an update. Dig Dis 2006;24:228-242.
5. Haag S, Talley NJ, Holtmann G: Symptom patterns in functional dyspepsia and irritable bowel syndrome: Relationship to disturbances in gastric emptying and response to a nutrient challenge in consulters and nonconsulters. Gut 2004;53:1445-1451.
6. Mayer EA, Tillisch K, Bradesi S: Review article: Modulation of the brain-gut axis as a therapeutic approach in gastrointestinal disease. Aliment Pharmacol Ther 2006;24:919-933.
7. Holtmann G, Goebell H, Talley NJ: Functional dyspepsia and irritable bowel syndrome: Is there a common pathophysiological basis? Am J Gastroenterol 1997;92:954-959.
8. Holtmann G, Stanghellini V, Talley NJ: Nomenclature of dyspepsia, dyspepsia subgroups and functional dyspepsia: Clarifying the concepts. Baillieres Clin Gastroenterol 1998;12:417-433.
9. Haag S, Senf W, Tagay S, Langkafel M, Braun-Lang U, Pietsch A, Heuft G, Talley NJ, Holtmann G: Is there a benefit from intensified medical and psychological interventions in patients with functional dyspepsia not responding to conventional therapy? Aliment Pharmacol Ther 2007;25:973-986.
10. Holtmann G, Kutscher SU, Haag S, Langkafel M, Heuft G, Neufang-Hueber J, Goebell H, Senf W, Talley NJ: Clinical presentation and personality factors are predictors of the response to treatment in patients with functional dyspepsia; a randomized, double-blind placebo-controlled crossover study. Dig Dis Sci 2004;49:672-679.
11. Kurth T, Holtmann G, Neufang-Huber J, Gerken G, Diener HC: Prevalence of unexplained upper abdominal symptoms in patients with migraine. Cephalalgia 2006;26:506-510.
12. Mason JM, Delaney B, Moayyedi P, Thomas M, Walt R: Managing dyspepsia without alarm signs in primary care: New national guidance for England and Wales. Aliment Pharmacol Ther 2005;21:1135-1143.
13. Veldhuyzen van Zanten SJ, Cleary C, Talley NJ, Peterson TC, Nyren O, Bradley LA, Verlinden M, Tytgat GN: Drug treatment of functional dyspepsia: A systematic analysis of trial methodology with recommendations for design of future trials. Am J Gastroenterol 1996;91:660-673.
14. Holtmann G, Talley NJ: Functional dyspepsia. Current treatment recommendations. Drugs 1993;45:918-930.
15. Malfertheiner P: Helicobacter pylori eradication in functional dyspepsia: New evidence for symptomatic benefit. Eur J Gastroenterol Hepatol 2001;13(suppl 2):S9-S11.
16. Moayyedi P, Deeks J, Talley NJ, Delaney B, Forman D: An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: Resolving the discrepancy between systematic reviews. Am J Gastroenterol 2003;98:2621-2626.
17. Moayyedi P, Soo S, Deeks J, Delaney B, Innes M, Forman D: Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006;4:CD001960.
18. Holtmann G, Talley NJ, Liebregts T, Adam B, Parow C: A placebo-controlled trial of itopride in functional dyspepsia. N Engl J Med 2006;354:832-840.
19. Enck P, Klosterhalfen S: The placebo response in functional bowel disorders: Perspectives and putative mechanisms. Neurogastroenterol Motil 2005;17:325-331.
20. Talley NJ, Locke GR, Lahr BD, Zinsmeister AR, Cohard-Radice M, D'Elia TV, Tack J, Earnest DL: Predictors of the placebo response in functional dyspepsia. Aliment Pharmacol Ther 2006;23:923-936.
21. Holtmann G, Gschossmann J, Mayr P, Talley NJ: A randomized placebo-controlled trial of simethicone and cisapride for the treatment of patients with functional dyspepsia. Aliment Pharmacol Ther 2002;16:1641-1648.
22. Smith RC, Talley NJ, Dent OF, Jones M, Waller SL: Exocrine pancreatic function and chronic unexplained dyspepsia. A case-control study. Int J Pancreatol 1991;8:253-262.
23. Jackson JL, O'Malley PG, Tomkins G, Balden E, Santoro J, Kroenke K: Treatment of functional gastrointestinal disorders with antidepressant medications:A meta-analysis. Am J Med 2000;108:65-72.
24. Foxx-Orenstein A, Camilleri M, Stephens D, Burton D: Effect of a somatostatin analogue on gastric motor and sensory functions in healthy humans. Gut 2003;52:1555-1561.
25. Schwetz I, Naliboff B, Munakata J, Lembo T, Chang L, Matin K, Ohning G, Mayer EA: Anti-hyperalgesic effect of octreotide in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2004;19:123-131.
26. Mertz H, Walsh JH, Sytnik B, Mayer EA: The effect of octreotide on human gastric compliance and sensory perception. Neurogastroenterol Motil 1995;7:175-185.
27. Rosch W, Vinson B, Sassin I: A randomised clinical trial comparing the efficacy of a herbal preparation STW 5 with the prokinetic drug cisapride in patients with dysmotility type of functional dyspepsia. Z Gastroenterol 2002;40:401-408.
28. Madisch A, Melderis H, Mayr G, Sassin I, Hotz J: [A plant extract and its modified preparation in functional dyspepsia. Results of a double-blind placebo controlled comparative study]. Z Gastroenterol 2001;39:511-517.
29. Madisch A, Holtmann G, Mayr G, Vinson B, Hotz J: Treatment of functional dyspepsia with a herbal preparation. A double-blind, randomized, placebo-controlled, multicenter trial. Digestion 2004;69:45-52.
30. Madisch A, Holtmann G, Plein K, Hotz J: Treatment of irritable bowel syndrome with herbal preparations: Results of a double-blind, randomized, placebo-controlled, multi-centre trial. Aliment Pharmacol Ther 2004;19:271-279.
31. Pilichiewicz AN, Horowitz M, Russo A, Maddox AF, Jones KL, Schemann M, Holtmann G, Feinle-Bisset C: Effects of Iberogast on proximal gastric volume, antropyloroduodenal motility and gastric emptying in healthy men. Am J Gastroenterol 2007;102:1276-1283.
32. Grigoleit HG, Grigoleit P: Peppermint oil in irritable bowel syndrome. Phytomedicine 2005;12:601-606.
33. Pittler MH, Ernst E: Peppermint oil for irritable bowel syndrome: A critical review and metaanalysis. Am J Gastroenterol 1998;93:1131-1135.
34. May B, Kohler S, Schneider B: Efficacy and tolerability of a fixed combination of peppermint oil and caraway oil in patients suffering from functional dyspepsia. Aliment Pharmacol Ther 2000;14:1671-1677.
35. Adam B, Liebregts T, Best J, Bechmann L, Lackner C, Neumann J, Koehler S, Holtmann G: A combination of peppermint oil and caraway oil attenuates the post-inflammatory visceral hyperalgesia in a rat model. Scand J Gastroenterol 2006;41:155-160.
36. Yamada K, Yagi G, Kanba S: Effectiveness of Gorei-san (TJ-17) for treatment of SSRI-induced nausea and dyspepsia: preliminary observations. Clin Neuropharmacol 2003;26:112-114.
37. Holtmann G, Adam B, Haag S, Collet W, Grunewald E, Windeck T: Efficacy of artichoke leaf extract in the treatment of patients with functional dyspepsia: A six-week placebo-controlled, double-blind, multicentre trial. Aliment Pharmacol Ther 2003;18:1099-1105.
38. Holtmann G, Haag S, Adam B, Funk P, Wieland V, Heydenreich CJ: Effects of a fixed combination of peppermint oil and caraway oil on symptoms and quality of life in patients suffering from functional dyspepsia. Phytomedicine 2003;10(suppl 4):56-57.
39. Boyce PM, Talley NJ, Balaam B, Koloski NA, Truman G: A randomized controlled trial of cognitive behavior therapy, relaxation training, and routine clinical care for the irritable bowel syndrome. Am J Gastroenterol 2003;98:2209-2218.
40. Chitkara D, Talley NJ: Hypnotherapy for functional dyspepsia: Do the results add up? Gastroenterology 2003;125:636; author reply 637.
41. Soo S, Forman D, Delaney BC, Moayyedi P: A systematic review of psychological therapies for nonulcer dyspepsia. Am J Gastroenterol 2004;99:1817-1822.
42. Whorwell PJ: Review article: The history of hypnotherapy and its role in the irritable bowel syndrome. Aliment Pharmacol Ther 2005;22:1061-1067.
43. Calvert EL, Houghton LA, Cooper P, Morris J, Whorwell PJ: Long-term improvement in functional dyspepsia using hypnotherapy. Gastroenterology 2002;123:1778-1785.
44. Holtmann G, Siffert W, Haag S, Mueller N, Langkafel M, Senf W, Zotz R, Talley NJ: G-protein beta 3 subunit 825 CC genotype is associated with unexplained (functional) dyspepsia. Gastroenterology 2004;126:971-979.